Nelfinavir Mesylate

产品说明书

Print
Chemical Structure| 159989-65-8 同义名 : AG 1343 Mesylate; Nelfinavir (mesylate); Nelfin; AG-1343
CAS号 : 159989-65-8
货号 : A228436
分子式 : C33H49N3O7S2
纯度 : 99%+
分子量 : 663.89
MDL号 : MFCD00931436
存储条件：

Pure form Keep in dark place, inert atmosphere, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(158.16 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
生物活性
靶点

  • HIV Protease

    HIV protease, Ki:2 nM
描述 Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Additionally, Nelfinavir Mesylate (AG 1343 Mesylate) exhibits broad-spectrum anticancer activity [1][2][3].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00002411 HIV Infections Not Applicable Completed - -
NCT00000895 Mycobacterium Avium-intracellu... 展开 >>lare Infection HIV Infections 收起 << Not Applicable Completed - -
NCT00122590 HIV Infections Not Applicable Terminated - France ... 展开 >> Service de Medecine Interne Hopital Cochin Paris, France, 75014 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.51mL

0.30mL

0.15mL

7.53mL

1.51mL

0.75mL

15.06mL

3.01mL

1.51mL
参考文献

[1]Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13(1):76-90.

[2]Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13(17):5183-94.

[3]Kaldor SW, et al. Nelfinavir mesylate (AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85.

[4]Bono C, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97(7):1101‐1109.

[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.